

Orlistat

Catalog No: tcsc2165



Available Sizes

Size: 100mg

Size: 200mg

Size: 500mg



Specifications

CAS No:

96829-58-2

Formula:

$C_{29}H_{53}NO_5$

Pathway:

Metabolic Enzyme/Protease

Target:

Fatty Acid Synthase (FAS)

Purity / Grade:

>98%

Solubility:

H₂O :

Alternative Names:

Tetrahydrolipstatin;Ro-18-0647

Observed Molecular Weight:

495.73


Product Description

Orlistat is a general lipase inhibitor with IC₅₀ of 122 ng/ml for PL from human duodenal juice.

Target: lipase inhibitor

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium *Streptomyces toxytricini*. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug. The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug over the course of a year.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!